MARKET

PFE

PFE

Pfizer
NYSE
30.77
+1.01
+3.39%
After Hours: 30.69 -0.08 -0.26% 19:59 07/26 EDT
OPEN
30.15
PREV CLOSE
29.76
HIGH
30.88
LOW
30.01
VOLUME
35.66M
TURNOVER
0
52 WEEK HIGH
37.80
52 WEEK LOW
24.48
MARKET CAP
174.36B
P/E (TTM)
-477.0543
1D
5D
1M
3M
1Y
5Y
1D
Catalyst Watch: Tech blitz with Apple, Amazon, Microsoft, and Meta on tap for earnings
Seeking Alpha's Catalyst Watch looks at next week's key events. Options trading volume is elevated on Container Store and Allbirds ahead of their earnings reports. McDonald's, Microsoft, and Boeing among companies due to report on July 29 and 30. Mark Zuckerberg will speak at the SIGGRAPH Conference in Denver.
Seeking Alpha · 7h ago
Noteworthy Friday Option Activity: PFE, FDX, JBHT
NASDAQ · 9h ago
Sangamo rallies for third day in wake of positive gene therapy results
Shares of Sangamo rallies for third day in wake of positive gene therapy results. Sangamo (SGMO) shares gained 40% on Wednesday and 20% on Thursday. Pfizer reported positive results for their gene therapy candidate giroctocogene fitelparvovec in the treatment of hemophilia A.
Seeking Alpha · 9h ago
3 Surprisingly Underrated Stocks to Buy Right Now
Three Motley Fool contributors think AstraZeneca, Pfizer and Viatris are underrated pharmaceutical stocks to buy. Astra Zeneca is a growth machine with impressive prospects. The company expects to generate as much as $80 billion in annual revenue by the end of the decade. These companies are undervalued and deserve more respect.
The Motley Fool · 9h ago
Pfizer Revises Incentive Plans for Employee and Shareholder Alignment
TipRanks · 10h ago
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
NASDAQ · 11h ago
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
NASDAQ · 12h ago
Benjamin Graham Detailed Fundamental Analysis - PFE
NASDAQ · 13h ago
More
About PFE
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Webull offers Pfizer Inc stock information, including NYSE: PFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PFE stock methods without spending real money on the virtual paper trading platform.